Implication of microRNA as a potential biomarker of myocarditis

Area of Science:

• Cardiology
• Immunology
• Molecular Biology

Background:

• Myocarditis etiology extends beyond viral infections to include other harmful agents.
• COVID-19 vaccine-associated myocarditis in pediatric populations highlights the need for further understanding.
• Pathology involves intricate immune responses, from innate and adaptive immunity to autoimmune reactions, potentially leading to cardiac failure.

Purpose of the Study:

• To review current knowledge on myocarditis, focusing on its pathophysiology and etiology.
• To explore the emerging role of microRNAs (miRNAs) as potential biomarkers and therapeutic targets in myocarditis.
• To discuss the implications of recent advancements in miRNA research for future myocarditis treatments.

Main Methods:

• Literature review of recent research on myocarditis and microRNAs.
• Analysis of the immunological pathways involved in myocarditis development.
• Examination of the role of specific microRNAs (e.g., miR-221/222, miR-155) in myocarditis.

Main Results:

• Myocarditis pathogenesis is complex, involving viral and non-viral triggers and multifaceted immune responses.
• Specific microRNAs, including miR-221/222, miR-155, miR-10a*, and miR-590, are associated with myocarditis.
• While direct clinical trials for miRNA intervention in myocarditis are pending, progress in other cardiac diseases and FDA-approved small-RNA therapies offer a positive outlook.

Conclusions:

• MicroRNAs represent a significant area of research for novel myocarditis biomarkers and therapeutic strategies.
• Understanding miRNA roles could lead to improved diagnostics and treatments for myocarditis and associated cardiac dysfunction.
• The success of miRNA-based therapies in other conditions supports their potential application in managing myocarditis.